Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Following massive global initiatives, the US Food and Drug Administration approved several SARS-CoV-2 vaccines, including the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. While manifestations of COVID-19 are heterogeneous, patients with solid tumors undergoing active therapy are at considerable risk for worse outcomes. Among these patients, humoral response to SARS-CoV-2 vaccines has been reported in approximately 90%. Although high, this proportion is considerably lower than the 99% to 100% found in control groups. Among patients who are treated with chemotherapy, further reduced humoral responses have been described.
JAMA Oncology , article en libre accès, 2020